ACM
CTKB icon

Aquatic Capital Management’s Cytek Biosciences CTKB Stock Holding History

Aquatic Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-306
Closed -$1.54K – 1460
2025
Q4 		$1.54K Sell
306
-83,844
-100% -$389K ﹤0.01% 1355
2025
Q3 		$292K Buy
84,150
+63,900
+316% +$240K 0.01% 1009
2025
Q2 		$68.8K Buy
20,250
+19,984
+7,513% +$66.6K ﹤0.01% 1122
2025
Q1 		$1.07K Sell
266
-3,519
-93% -$18.2K ﹤0.01% 1210
2024
Q4 		$24.6K Buy
+3,785
New +$22.5K ﹤0.01% 1226

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aquatic Capital Management's CTKB Position: Q1 2026 in Review

Aquatic Capital Management sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 306 shares — an estimated $1.54K sold.

Aquatic Capital Management first reported a position in CTKB in Q4 2024 and held it in 5 quarters. The position peaked at $292K in Q3 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Aquatic Capital Management reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 306 Cytek Biosciences shares in Q1 2026, an estimated $1.54K.
  • Aquatic Capital Management first reported a position in Cytek Biosciences in Q4 2024 and held it in 5 quarters.
  • Aquatic Capital Management's Cytek Biosciences position peaked at $292K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.